Tirzepatide

Tirzepatide Product Introduction

Overview Tirzepatide is a once‑weekly, single‑molecule dual agonist of the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors, developed by Eli Lilly. It is the first and only approved GIP/GLP‑1 dual receptor agonist, with regulatory approvals in multiple markets for type 2 diabetes (T2DM) and, in some regions, for weight management and obstructive sleep apnea (OSA). In China, the brand name is Mounjaro